Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Liu, Qiang ^a   Zhou, Shuya ^a   Fan, Changfa ^a   Huang, Weijin ^a   Li, Qianqian ^a   Liu, Susu ^a   Wu, Xi ^a   Li, Baowen ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; FIREFLY LUCIFERASE;

ADMINISTRATION AND DOSAGE; ANIMAL; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUMINESCENCE; MOUSE; PHARMACOKINETICS; RAT; REPORTER GENE; STAINING; TIME FACTOR; WHOLE BODY IMAGING;

ADENOVIRUSES, HUMAN; ADMINISTRATION, INTRAVENOUS; ANIMALS; DRUG CARRIERS; GENES, REPORTER; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MICE; RATS; STAINING AND LABELING; TIME FACTORS; WHOLE BODY IMAGING;

EID: 85020927843     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-03852-0     Document Type: Article

References (46)

1. Schenk-Braat, E. A., van Mierlo, M. M., Wagemaker, G., Bangma, C. H., Kaptein, L. C. An inventory of shedding data from clinicalgene therapy trials. J Gene Med 9, 910-921 (2007).
2. Reid, T., Warren, R., Kirn, D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 9, 979-986 (2002).
3. Hammer, S. M., et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369, 2083-2092 (2013).
4. Majhen, D., et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: Progress in the field. Hum Gene Ther 25, 301-317 (2014).
5. Raper, S. E., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient followingadenoviral gene transfer. Mol Genet Metab 80, 148-158 (2003).
6. Teich, N., et al. Vaccination coverage in immunosuppressed patients: Results of a regional health services research study. Dtsch ArzteblInt 108, 105-111 (2011).
7. Fraser, C., et al. Pandemic potential of a strain of influenza A (H1N1): Early findings. Science. 324, 1557-1561 (2009).
8. George, M. P., et al. Infections in the immunosuppressed host. Ann Am Thorac Soc. 11(Suppl 4), S211-220 (2014).
9. Liu, Q., et al. Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model forhuman smallpox. Sci Rep 5, 11397 (2015).
10. Pan, W., et al. Visualizing influenza virus infection in living mice. Nat Commun. 4, 2369 (2013).
11. Shinkai, Y., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68, 855-867 (1992).
12. Abbott, A. Laboratory animals: The Renaissance rat. Nature. 428, 464-466 (2004).
13. Ying, B., et al. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrianhamsters. Antimicrob Agents Chemother 58, 7171-7181 (2014).
14. Toth, K., et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressedanimal model. Proc Natl Acad Sci USA 105, 7293-7297 (2008).
15. Alemany, R., Suzuki, K., Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81, 2605-2609 (2000).
16. Mozdzanowska, K., Maiese, K., Gerhard, W. Th cell-deficient mice control influenza virus infection more effectively than Th-A ndB cell-deficient mice: Evidence for a Th-independent contribution by B cells to virus clearance. J Immunol. 164, 2635-2643 (2000).
17. Lee, B. O., et al. CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to preventreinfection. J Immunol. 175, 5827-5838 (2005).
18. Shayakhmetov, D. M., Li, Z. Y., Ni, S., Lieber, A. Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors. J Virol. 78, 5368-5381 (2004).
19. Zhou, S., et al. A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice. Vaccine. 34, 2729-2736 (2016).
20. Guse, K., et al. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther 14, 902-911 (2007).
21. Tatsis, N., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: Implications for their use as vaccines. Blood.110, 1916-1923 (2007).
22. Hiltunen, M. O., et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall usingintravascular and periadventitial gene delivery methods. FASEB J 14, 2230-2236 (2000).
23. Stone, D., et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. JVirol. 81, 4866-4871 (2007).
24. Kadurugamuwa, J. L., et al. Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneousimaging, in vivo, of the pathogen and host response. Infect Immun. 73, 7836-7843 (2005).
25. Gregory, S. M., Nazir, S. A., Metcalf, J. P. Implications of the innate immune response to adenovirus and adenoviral vectors. FutureVirol. 6, 357-374 (2011).
26. Cameron, M. J., et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immuneresponses in patients with severe acute respiratory syndrome. J Virol. 81, 8692-8706 (2007).
27. de Jong, M. D., et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med12, 1203-1207 (2006).
28. Shayakhmetov, D. M., Li, Z. Y., Ni, S., Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, innate toxicity after injection of fiber-modified vectors. J Virol. 78, 5368-5381 (2004).
29. Lozier, J. N., et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 13, 113-124 (2002).
30. Engler, H., et al. Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a andinduction of TNF-alpha. Virology. 328, 52-61 (2004).
31. Rubenfeld, G. D., et al. Incidence and outcomes of acute lung injury. N Engl J Med 353, 1685-1693 (2005).
32. Xu, L., et al. Cutting edge: Pulmonary immunopathology mediated by antigen-specific expression of TNF-alpha by antiviral CD8+T cells. J Immunol. 173, 721-725 (2004).
33. Muruve, D. A., Barnes, M. J., Stillman, I. E., Libermann, T. A. Adenoviral gene therapy leads to rapid induction of multiplechemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10, 965-976 (1999).
34. Lieber, A., et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinantadenovirus vectors. J Virol. 71, 8798-8807 (1997).
35. Maier, R., et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabeticpatients. Mol Vis. 14, 637-643 (2008).
36. Liu, Q., et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 14, 627-643 (2003).
37. Brunetti-Pierri, N., et al. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liverdirectedgene therapy. Mol Ther. 15, 732-740 (2007).
38. Ng, P., et al. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 10, 2667-2672 (1999).
39. Yu, S., et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, Sendai virusvectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine. 26, 6124-6131 (2008).
40. Maeda, M., et al. Targeted gene therapy toward astrocytoma using a Cre/loxP-based adenovirus system. Brain Res. 1081, 34-43(2006).
41. Nicholson, O., et al. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of HealthyAdults. AIDS Res Hum Retroviruses (2010).
42. Lang, F. F., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J ClinOncol 21, 2508-2518 (2003).
43. Zaitseva, M., et al. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J Virol. 83, 10437-10447 (2009).
44. Sun, P., et al. CD40 ligand enhances dengue viral infection of dendritic cells: A possible mechanism for T cell-mediatedimmunopathology. J Immunol. 177, 6497-6503 (2006).
45. Shrestha, B., et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol. 80, 5338-5348 (2006).
46. Yu, X. L., et al. Measles virus infection in adults induces production of IL-10 and is associated with increased CD4+ CD25+regulatory T cells. J Immunol. 181, 7356-7366 (2008).